Jacksonville is angling for a front-row seat in the next era of heart care, with a local research site preparing to test a one-time gene-editing treatment for inherited high cholesterol. ENCORE Research Group's Jacksonville Center for Clinical Research is opening an early-stage trial that will attempt to edit liver genes tied to dangerously high LDL levels and, in the process, cut lifelong cardiovascular risk. The experimental study is aimed at people with familial hypercholesterolemia, an inherited condition that can trigger heart attacks or require heart procedures before age 65, and it will enroll only a small number of tightly monitored volunteers.
Doctor Michael Koren, an investigator with ENCORE Research Group, told News4JAX that "we could be the first place in the United States, in all of the US, to do gene editing studies for cholesterol issues." According to the News4JAX report, the therapy is designed to act on the liver, and participants are expected to be followed for roughly 15 years to track safety - a long haul that lines up with FDA recommendations for genome-editing products. Local clinicians and patients are already pressing for details on who might qualify and what the screening process will look like.
Familial hypercholesterolemia (FH) is a genetic disorder that sharply raises LDL cholesterol and the risk of early cardiovascular disease. Genetic summaries put heterozygous FH at about 1 in 250 to 1 in 300 people in many populations, which means thousands of Floridians could meet criteria for intensified care or referral into studies. Because FH works through faulty liver pathways that normally clear LDL, researchers say the liver is a logical target for precise, durable interventions instead of relying only on lifelong pills. GeneReviews outlines the prevalence figures and clinical toll of the condition.
How the treatments work and where they fit
Not all gene-editing strategies are created equal, but many of the cholesterol-focused approaches under study share a core idea: permanently turning off genes that boost LDL. Verve Therapeutics, for instance, uses base editing directed at the PCSK9 gene in the liver and has reported dose-dependent LDL reductions in early Heart trials, illustrating the "one-and-done" outcome sponsors are chasing. Another strategy - CRISPR-Cas9 editing of the ANGPTL3 gene - showed large, durable lipid reductions in a small Phase 1 study published in the New England Journal of Medicine, a sign that the field is quickly branching out in both targets and delivery methods.
Safety and long-term monitoring
Because gene editing creates a permanent change in DNA, regulators expect a marathon of safety follow-up, not a sprint. FDA guidance recommends long-term observation, often up to 15 years, for investigational genome-editing products. Institutions running first-in-human studies have built that expectation into their plans: the Cleveland Clinic, for example, describes a core follow-up period plus additional long-term safety monitoring in line with FDA recommendations. Experts emphasize that any early success in lowering LDL has to be weighed against years of safety data before these therapies could be rolled out widely.
Local enrollment and how to learn more
ENCORE Research Group has posted a Jacksonville study listing for a cholesterol trial labeled AZURE-LDL, inviting qualified volunteers to contact the site for screening. The study page lays out enrollment criteria and contact information for the Jacksonville Center for Clinical Research, and interested people are urged to review the listing and talk it over with their cardiologist or primary care doctor before jumping in. ENCORE Research Group maintains the patient-facing page with study details and next steps.
Researchers caution that this trial is an early move, not an instant cure. Larger studies and longer follow-up will be needed to determine who benefits most and how safe a one-time edit really is over decades. For now, people with very high cholesterol or a strong family history of early heart disease are being urged to stick with prescribed treatments and to ask their clinicians about lipid specialist referrals or appropriate clinical trial options.
